UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
May
30, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th Floor
New
York, NY 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
BIOPHARMACEUTICALS LTD. PUBLISHES PROSPECTUS FOR SECURITIES ISSUED PURSUANT
TO
THE PRIVATE PLACEMENT COMPLETED IN MARCH 2006
New
York, New York , May 22, 2006 -
XTL
Biopharmaceuticals Ltd., (NASDAQ: XTLB; LSE: XTL; TASE: XTL) (”XTLbio”), a
biotechnology company focused on the acquisition, development and
commercialization of therapeutics for the treatment of infectious diseases,
with
a focus on hepatitis C, announced today that it has published a prospectus
with
the United Kingdom Listing Authority in relation to the issuance of 46,666,670
new ordinary shares under the private placement that was completed in March
2006. A registration statement on Form F-1 that was filed by XTLbio in April
2006 is expected to be declared effective by the United States Securities and
Exchange Commission later today. XTLbio expects that the 46,666,670 new ordinary
shares will be listed on the Official List and be admitted to trading on the
London Stock Exchange’s market for listed securities on Thursday, May 25, 2006.
ADR’s representing those ordinary shares will begin to trade on Nasdaq
thereafter.
ABOUT
XTL BIOPHARMACEUTICALS, LTD. XTLbio
is
engaged in the acquisition, development and commercialization of therapeutics
for the treatment of infectious diseases, with a focus on hepatitis C. XTL
is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase - presently in Phase 1 clinical trials in patients
with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of
two
monoclonal antibodies against the hepatitis C virus - presently in Phase 1
clinical trials in patients with chronic hepatitis C. XTLbio’s hepatitis C
pipeline also includes several families of pre-clinical hepatitis C small
molecule inhibitors. In addition, XTL has out-licensed to Cubist Pharmaceuticals
an antibody therapeutic against hepatitis B, HepeX-B, which has recently
completed a Phase 2b clinical study in hepatitis B liver transplant patients.
XTL is publicly traded on the Nasdaq, London, and Tel-Aviv Stock Exchanges
(NASDAQ: XTLB; LSE: XTL; TASE: XTL).
This
press release and prior releases are available at http://www.xtlbio.com. The
information in our website is not incorporated by reference into this press
release and is included as an inactive textual reference only.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
|
|
| |
XTL
BIOPHARMACEUTICALS LTD. |
|
|
|
| Date: May
30,
2006 |
By: |
/s/ Jonathan
Burgin |
| |
Jonathan
Burgin |
| |
Chief
Financial Officer |